Genomic Cancer Testing Market Size, Share & Trends Analysis Report By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Other specialized genomic tests), By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Region, And By Segment Forecasts, 2025-2034
Segmentation of Genomic Cancer Testing Market-
Genomic Cancer Testing Market By Test Type-
- Genomic Profiling Tests
- Liquid Biopsy Tests
- Companion Diagnostic Tests
- Pharmacogenomic Tests
- Hereditary Cancer Tests
- Other specialized genomic tests
Genomic Cancer Testing Market By Cancer Type-
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer
- Melanoma
- Leukaemia
- Lymphoma
- Other specific cancer types
Genomic Cancer Testing Market By Technology-
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In Situ Hybridization (FISH)
- Microarray
- Immunohistochemistry (IHC)
- Other genomic testing technologies
Genomic Cancer Testing Market By End-User-
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutions
- Cancer Centers
- Other healthcare providers
Genomic Cancer Testing Market By Biomarker Type-
- Genetic Biomarkers
- Protein Biomarkers
- Molecular Biomarkers
- Epigenetic Biomarkers
Genomic Cancer Testing Market By Service Provider-
- Diagnostic Laboratories
- Biotechnology Companies
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
Genomic Cancer Testing Market By Application-
- Targeted Therapy Selection
- Disease Monitoring
- Prognostic Testing
- Companion Diagnostics
- Risk Assessment
- Pharmacogenomic Testing
Genomic Cancer Testing Market By Testing Setting-
- In-House Testing
- Outsourced Testing
Genomic Cancer Testing Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Genomic Cancer Testing Market Snapshot
Chapter 4. Global Genomic Cancer Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. By Technology, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
5.2.1. Next-Generation Sequencing (NGS)
5.2.2. Polymerase Chain Reaction (PCR)
5.2.3. Fluorescence In Situ Hybridization (FISH)
5.2.4. Microarray
5.2.5. Immunohistochemistry (IHC)
5.2.6. Other genomic testing technologies
Chapter 6. Market Segmentation 2: By Test Type Estimates & Trend Analysis
6.1. By Test Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Test Type:
6.2.1. Genomic Profiling Tests
6.2.2. Liquid Biopsy Tests
6.2.3. Companion Diagnostic Tests
6.2.4. Pharmacogenomic Tests
6.2.5. Hereditary Cancer Tests
6.2.6. Other specialized genomic tests
Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis
7.1. By Cancer Type & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cancer Type:
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Ovarian Cancer
7.2.6. Melanoma
7.2.7. Leukemia
7.2.8. Lymphoma
7.2.9. Other specific cancer types
Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis
8.1. By End-User & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-User:
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
8.2.3. Academic and Research Institutions
8.2.4. Cancer Centers
8.2.5. Other healthcare providers
Chapter 9. Market Segmentation 5: By Biomarker Type Estimates & Trend Analysis
9.1. By Biomarker Type & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Biomarker Type:
9.2.1. Genetic Biomarkers
9.2.2. Protein Biomarkers
9.2.3. Molecular Biomarkers
9.2.4. Epigenetic Biomarkers
Chapter 10. Market Segmentation 6: By Service Provider Estimates & Trend Analysis
10.1. By Service Provider & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service Provider:
10.2.1. Diagnostic Laboratories
10.2.2. Biotechnology Companies
10.2.3. Pharmaceutical Companies
10.2.4. Contract Research Organizations (CROs)
Chapter 11. Market Segmentation 7: By Application Estimates & Trend Analysis
11.1. By Application & Market Share, 2024 & 2034
11.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
11.2.1. Targeted Therapy Selection
11.2.2. Disease Monitoring
11.2.3. Prognostic Testing
11.2.4. Companion Diagnostics
11.2.5. Risk Assessment
11.2.6. Pharmacogenomic Testing
Chapter 12. Market Segmentation 8: By Testing Setting Estimates & Trend Analysis
12.1. By Testing Setting & Market Share, 2024 & 2034
12.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Testing Setting:
12.2.1. In-House Testing
12.2.2. Outsourced Testing
Chapter 13. Genomic Cancer Testing Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. North America
13.1.1. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Technology, 2021-2034
13.1.2. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Test Type, 2021-2034
13.1.3. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Cancer Type, 2021-2034
13.1.4. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By End-User, 2021-2034
13.1.5. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Biomarker Type, 2021-2034
13.1.6. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Service Provider, 2021-2034
13.1.7. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Application, 2021-2034
13.1.8. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Testing Setting, 2021-2034
13.1.9. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts by country, 2021-2034
13.2. Europe
13.2.1. Europe Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.2.2. Europe Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.2.3. Europe Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.2.4. Europe Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.2.5. Europe Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.2.6. Europe Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.2.7. Europe Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.2.8. Europe Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.2.9. Europe Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.3. Asia Pacific
13.3.1. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.3.2. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.3.3. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.3.4. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.3.5. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.3.6. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.3.7. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.3.8. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.3.9. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.4. Latin America
13.4.1. Latin America Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.4.2. Latin America Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.4.3. Latin America Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.4.4. Latin America Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.4.5. Latin America Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.4.6. Latin America Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.4.7. Latin America Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.4.8. Latin America Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.4.9. Latin America Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.5. Middle East & Africa
13.5.1. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.5.2. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.5.3. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.5.4. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.5.5. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.5.6. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.5.7. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.5.8. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.5.9. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. Illumina, Inc.,
14.2.2. Thermo Fisher Scientific, Inc.,
14.2.3. Qiagen N.V.,
14.2.4. F. Hoffmann-La Roche Ltd.,
14.2.5. Foundation Medicine, Inc. (Roche),
14.2.6. Invitae Corporation,
14.2.7. NeoGenomics Laboratories, Inc.,
14.2.8. Myriad Genetics, Inc.,
14.2.9. Genomic Health, Inc. (Exact Sciences Corporation),
14.2.10. Caris Life Sciences,
14.2.11. ArcherDX, Inc. (Invitae Corporation),
14.2.12. Guardant Health, Inc.,
14.2.13. Personal Genome Diagnostics Inc.,
14.2.14. Biocept, Inc.,
14.2.15. Tempus Labs, Inc.
14.2.16. Danaher
14.2.17. PerkinElmer
14.2.18. Agilent Technologies, Inc
14.2.19. Quest Diagnostics
14.2.20. Luminex Corporation
14.2.21. Others
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Genomic Cancer Testing Market Size is valued at USD 18.47 billion in 2024 and is predicted to reach USD 86.13 billion by the year 2034
Genomic Cancer Testing Market expected to grow at a 16.8% CAGR during the forecast period for 2025-2034.
Biocept, Inc., and Tempus Labs, Inc., Danaher, PerkinElmer, Agilent Technologies, Inc., Quest Diagnostics, Luminex Corporation
Genomic Cancer Testing Market is segmented based on test type, cancer type, technology, end-user, biomarker type, service provider, application, and t
North America region is leading the Genomic Cancer Testing Market.